These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
221 related articles for article (PubMed ID: 26362393)
1. Relationship between mono-hydroxy-carbazepine serum concentrations and adverse effects in patients on oxcarbazepine monotherapy. Sattler A; Schaefer M; May TW Seizure; 2015 Sep; 31():149-54. PubMed ID: 26362393 [TBL] [Abstract][Full Text] [Related]
2. Relationship between serum mono-hydroxy-carbazepine concentrations and adverse effects in patients with epilepsy on high-dose oxcarbazepine therapy. Striano S; Striano P; Di Nocera P; Italiano D; Fasiello C; Ruosi P; Bilo L; Pisani F Epilepsy Res; 2006 May; 69(2):170-6. PubMed ID: 16515857 [TBL] [Abstract][Full Text] [Related]
3. Oxcarbazepine and adverse events: impact of age, dosage, metabolite serum concentrations and concomitant antiepileptic therapy. Ortenzi A; Paggi A; Foschi N; Sabbatini D; Pistoli E Funct Neurol; 2008; 23(2):97-100. PubMed ID: 18671911 [TBL] [Abstract][Full Text] [Related]
4. Drug interaction and pharmacokinetic modeling of oxcarbazepine in korean patients with epilepsy. Park KJ; Kim JR; Joo EY; Seo DW; Hong SB; Ko JW; Kim SR; Huh W; Lee SY Clin Neuropharmacol; 2012; 35(1):40-4. PubMed ID: 22246398 [TBL] [Abstract][Full Text] [Related]
5. Effects of UGT1A9 genetic polymorphisms on monohydroxylated derivative of oxcarbazepine concentrations and oxcarbazepine monotherapeutic efficacy in Chinese patients with epilepsy. Lu Y; Fang Y; Wu X; Ma C; Wang Y; Xu L Eur J Clin Pharmacol; 2017 Mar; 73(3):307-315. PubMed ID: 27900402 [TBL] [Abstract][Full Text] [Related]
6. Short-term impact of the switch from immediate-release to extended-release oxcarbazepine in epilepsy patients on high dosages. Steinhoff BJ; Wendling AS Epilepsy Res; 2009 Dec; 87(2-3):256-9. PubMed ID: 19850448 [TBL] [Abstract][Full Text] [Related]
7. Usefulness of oral loading of oxcarbazepine suspension in selected patients with epilepsy. Kim DW; Gu N; Lee H; Jang IJ; Chu K; Yu KS; Cho JY; Yoon SH; Na HJ; Lee SK Int J Clin Pharmacol Ther; 2013 Oct; 51(10):780-6. PubMed ID: 23849326 [TBL] [Abstract][Full Text] [Related]
8. Risk factors of oxcarbazepine-induced hyponatremia in patients with epilepsy. Lin CH; Lu CH; Wang FJ; Tsai MH; Chang WN; Tsai NW; Lai SL; Tseng YL; Chuang YC Clin Neuropharmacol; 2010; 33(6):293-6. PubMed ID: 20881597 [TBL] [Abstract][Full Text] [Related]
9. Feasibility and limitations of oxcarbazepine monitoring using salivary monohydroxycarbamazepine (MHD). Miles MV; Tang PH; Ryan MA; Grim SA; Fakhoury TA; Strawsburg RH; DeGrauw TJ; Baumann RJ Ther Drug Monit; 2004 Jun; 26(3):300-4. PubMed ID: 15167632 [TBL] [Abstract][Full Text] [Related]
10. Vitamin D levels and bone turnover in epilepsy patients taking carbamazepine or oxcarbazepine. Mintzer S; Boppana P; Toguri J; DeSantis A Epilepsia; 2006 Mar; 47(3):510-5. PubMed ID: 16529614 [TBL] [Abstract][Full Text] [Related]
12. Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers. Antunes Nde J; Wichert-Ana L; Coelho EB; Della Pasqua O; Alexandre Junior V; Takayanagui OM; Tozatto E; Marques MP; Lanchote VL Eur J Clin Pharmacol; 2016 Feb; 72(2):195-201. PubMed ID: 26514967 [TBL] [Abstract][Full Text] [Related]
13. Neurological adverse events of new generation sodium blocker antiepileptic drugs. Meta-analysis of randomized, double-blinded studies with eslicarbazepine acetate, lacosamide and oxcarbazepine. Zaccara G; Giovannelli F; Maratea D; Fadda V; Verrotti A Seizure; 2013 Sep; 22(7):528-36. PubMed ID: 23623245 [TBL] [Abstract][Full Text] [Related]
14. Effects of carbamazepine and oxcarbazepine on the reproductive endocrine function in women with epilepsy. Löfgren E; Tapanainen JS; Koivunen R; Pakarinen A; Isojärvi JI Epilepsia; 2006 Sep; 47(9):1441-6. PubMed ID: 16981858 [TBL] [Abstract][Full Text] [Related]
15. Temozolomide treatment does not affect topiramate and oxcarbazepine plasma concentrations in chronically treated patients with brain tumor-related epilepsy. Maschio M; Albani F; Jandolo B; Zarabla A; Contin M; Dinapoli L; Fabi A; Pace A; Baruzzi A J Neurooncol; 2008 Nov; 90(2):217-21. PubMed ID: 18612799 [TBL] [Abstract][Full Text] [Related]
16. Oxcarbazepine-induced hyponatremia and the regulation of serum sodium after replacing carbamazepine with oxcarbazepine in children. Holtmann M; Krause M; Opp J; Tokarzewski M; Korn-Merker E; Boenigk HE Neuropediatrics; 2002 Dec; 33(6):298-300. PubMed ID: 12571784 [TBL] [Abstract][Full Text] [Related]
17. [Oxcarbazepine in the treatment of epilepsy. A review and update]. Horga de la Parte JF; Horga A Rev Neurol; 2006 Jan 16-31; 42(2):95-113. PubMed ID: 16450324 [TBL] [Abstract][Full Text] [Related]
18. Changes in the disposition of oxcarbazepine and its metabolites during pregnancy and the puerperium. Mazzucchelli I; Onat FY; Ozkara C; Atakli D; Specchio LM; Neve AL; Gatti G; Perucca E Epilepsia; 2006 Mar; 47(3):504-9. PubMed ID: 16529613 [TBL] [Abstract][Full Text] [Related]
19. Saliva and Plasma Monohydroxycarbamazepine Concentrations in Pediatric Patients With Epilepsy. Li RR; Sheng XY; Ma LY; Yao HX; Cai LX; Chen CY; Zhu SN; Zhou Y; Wu Y; Cui YM Ther Drug Monit; 2016 Jun; 38(3):365-70. PubMed ID: 26818624 [TBL] [Abstract][Full Text] [Related]
20. Conversion from carbamazepine or oxcarbazepine to topiramate in adolescents and adults with epilepsy. Kowalik A; Rimpau W; Adam H; Kühn F; van Oene J; Schreiner A; Bogdanow M; Schauble B; Acta Neurol Scand; 2008 Mar; 117(3):159-66. PubMed ID: 18218062 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]